A Pharmacokinetic/pharmacodynamic study to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.

Trial Profile

A Pharmacokinetic/pharmacodynamic study to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Feb 2016

At a glance

  • Drugs Ceftaroline fosamil (Primary)
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2016 According to Allergan media release, the U.S. Food and Drug Administration (FDA) has accepted for filing the company's supplemental New Drug Application (sNDA) for TEFLARO (ceftaroline fosamil).
    • 04 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top